COVID-19 is known to cause loss of smell in certain patients. While this symptom is generally temporary, approximately 10% of patients may suffer from it for 6 months or more.
Earlier research carried out by a team of researchers from INRAE and ENVA observed that the SARS-CoV-2 infected olfactory mucosa is invaded by immune cells leading to its destruction and prolonged inflammation. Based on these observations, the same team decided to assess the effectiveness of corticosteroids--known for their anti-inflammatory properties-;in restoring the sense of smell.
Their results support the existence of a direct link between the loss of smell caused by the virus and a decrease in the olfactory neuron population in the nasal mucosa. In addition, they show that early treatment with dexamethasone, a commonly used corticosteroid, improves the recovery of olfactory abilities in animals.
The improvement of the olfactory capacities is associated with a reduction of the immunity cells in the mucosa, and an increased level of regeneration of the olfactory neuron population. These results suggest that the corticosteroid treatments currently used-;which have not been very successful in the treatment of prolonged anosmia-;could be more effective if prescribed early, at the onset of symptoms of loss of smell.
Source:
Journal reference:
Merle-Nguyen, L., et al. (2024). Early corticosteroid treatment enhances recovery from SARS-CoV-2 induced loss of smell in hamster. Brain, Behavior, and Immunity. doi.org/10.1016/j.bbi.2024.02.020.
Research links COVID-19 vaccines to temporary facial palsy in over 5,000 patients